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The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers 
for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/
GCG) receptor agonism, are currently unavailable. Here, we investigated [68Ga]Ga-DO3A-S01-GCG 
as a biomarker for GCGR occupancy in liver, the tissue with highest GCGR expression, in non-human 
primates (NHP) by PET. [68Ga]Ga-DO3A-S01-GCG was evaluated by dynamic PET in NHPs by a dose 
escalation study design, where up to 67 µg/kg DO3A-S01-GCG peptide mass was co-injected. The 
test-retest reproducibility of [68Ga]Ga-DO3A-S01-GCG binding in liver was evaluated. Furthermore, 
we investigated the effect of pre-treatment with acylated glucagon agonist 1-GCG on [68Ga]Ga-
DO3A-S01-GCG binding in liver. [68Ga]Ga-DO3A-S01-GCG bound to liver in vivo in a dose-dependent 
manner. Negligible peptide mass effect was observed for DO3A-S01-GCG doses <0.2 µg/kg. In vivo Kd 
for [68Ga]Ga-DO3A-S01-GCG corresponded to 0.7 µg/kg, which indicates high potency. The test-retest 
reproducibility for [68Ga]Ga-DO3A-S01-GCG binding in liver was 5.7 ± 7.9%. Pre-treatment with 1-GCG, 
an acylated glucagon agonist, resulted in a GCGR occupancy of 61.5 ± 9.1% in liver. Predicted human 
radiation dosimetry would allow for repeated annual [68Ga]Ga-DO3A-S01-GCG PET examinations. 
In summary, PET radioligand [68Ga]Ga-DO3A-S01-GCG is a quantitative biomarker of in vivo GcGR 
occupancy.
The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Dual Glucagon-Like Peptide-1 
(GLP-1)/glucagon (GCG) receptor agonists have shown promising therpeutic effects, including weight loss 
and glycaemic control in preclinical and early clinical settings1–3. The lack of quantitative biomarkers for mon-
itoring in vivo occupancy at the GCGR, as part of the overlapping dual pharmacology of GLP-1/GCG recep-
tor agonists, makes drug candidate selection and optimisation difficult. Direct measurement of occupancy of 
each receptor as a function of in vivo exposure could help to unravel the pharmacological basis of the different 
physiological effects of GLP-1/GCG receptor agonists. The Positron Emission Tomography (PET) radioligand 
[68Ga]Ga-DO3A-VS-Cys40-Exendin-4 was previously developed for quantification of GLP-1R occupancy in the 
pancreas4.
Recently, we presented a series of first-in-class GCGR PET radioligands, based on rationally designed pep-
tide sequences, with high affinity and specificity towards the GCGR5,6. The analogues labelled with Gallium-68 
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maintained suitable affinity and selectivity for the GCGR and demonstrated negligible off-target binding on the 
GLP-1 receptor. One of the analogues, in particular, [68Ga]Ga-DO3A-S01-GCG (Fig. 1A,C), exhibited strong 
specific in vivo binding in rat liver, the relevant tissue for GCGR directed therapy.
In this study, we further evaluated [68Ga]Ga-DO3A-S01-GCG in non-human primate (NHP) as a first-in-class, 
quantitative biomarker of in vivo GCGR occupancy.
Materials and Methods
Radiochemistry. Gallium-68 radiolabeling of DO3A-S01-GCG (Fig. 1A) was performed as described 
previously5.
Non-human primate handling, housing and anaesthesia. PET/CT imaging was performed in NHPs 
(cynomolgus monkeys, n = 12, 11 female and 1 male, weight 5.1 ± 1.1, range 3.4–6.7 kg), which were housed in 
the Astrid Fagraeus Laboratory (AFL) at the Karolinska Institutet, Solna, Sweden. They were transported to the 
PET facility at the morning of each experiment. Two different PET imaging facilities were used in this study: 
Uppsala University Hospital (UUH) and Karolinska Institutet PET centre (KI).
Anaesthesia was induced by intramuscular injection of ketamine hydrochloride (10 mg/kg) at the housing 
facility. Two venous catheters were applied after induction of anaesthesia; one for PET radiopharmaceutical 
administration and one for blood sampling. Anaesthesia was maintained by the administration of a mixture 
of 1.5–2.0% isoflurane (KI) or 1–4% sevoflurane (UUH), oxygen and medical air after endotracheal intubation 
at each PET centre. Body temperature was maintained throughout the examination by a Bair Hugger (Arizant 
Healthcare, MN). Body temperature, ECG, heart rate, respiratory rate, oxygen saturation, blood pressure and 
B-glucose were monitored throughout the experiments. Fluid balance was maintained by a continuous infu-
sion of saline or Ringer’s Acetate, supplemented with glucose if needed. The procedures involving NHPs at both 
sites were approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency and carried out in 
accordance with the relevant national and institutional guidelines (UU: “Uppsala university guidelines on ani-
mal experimentation”, UFV 2007/724, KI: “Guidelines for planning, conducting and documenting experimental 
research”, Dnr 4820/06-600).
(D-Ser)QGTFTSDYSKQLDE*QRAK*EFIEWLLATGPESGAPPPS
[68Ga]Ga-DO3A-S01-GCG * Lactam bridge
(D-Ser)QGTFTSDYSKQK(gE-C16)ESRRAQEFIEWLLAGGPESGAPPPSNH2






Figure 1. Structures and GCGR binding model of [68Ga]Ga-DO3A-S01-GCG (A,C) and the acylated selective 
GCGR agonist 1-GCG (B,D). The binding model is based on the full-length structure of the GCGR (pdb code: 
5yqz). Structural receptor-peptide binding models and images were generated using maestro and PyMOL 
(Schrödinger, LLC, New York, NY).
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PET procedures: dose escalation studies. Dose escalation studies were performed in seven NHPs 
(n = 7, weight 5.0 ± 1.1, range 3.4–6.7 kg) with up to three sequential PET examinations performed in each NHP 
for each experimental day. The examinations were performed 2–3 hours apart to allow for radioactivity excre-
tion and radionuclide decay (t½ = 68 minutes). Each subsequent administration contained gradually increasing 
amounts of co-injected DO3A-S01-GCG peptide, thus, respectively decreasing the [68Ga]Ga-DO3A-S01-GCG 
tracer molar activity (previously referred to as specific radioactivity) value (MBq/nmol) (Table 1). For the high 
competing doses, unlabelled DO3A-S01-GCG was added to the [68Ga]Ga-DO3A-S01-GCG injection solution in 
order to reach the desired peptide mass.
Each animal was positioned to include the abdomen in the Field of View (FOV).
At the UUH site, the examination was conducted using a Discovery IQ PET/CT scanner (15 cm FOV, approx-
imately 5 mm resolution, GE Healthcare, Milwaukee, MI, USA). Attenuation correction was acquired by a 140 kV, 
Auto mA 10–80 mA CT examination. Dynamic PET measurements were acquired over 90 minutes in list mode.
At the KI facility, stand-alone PET measurements were conducted using a High Resolution Research 
Tomograph (HRRT) (approximately 3 mm resolution, Siemens Molecular Imaging). A transmission scan of 6 min 
using a single 137Cs source was performed for attenuation correction of PET images. Dynamic PET measurements 
were acquired over 93 minutes in list mode.
Venous blood samples for radioactivity measurement in whole blood and plasma were taken 5, 30 and 60 min 
after [68Ga]Ga-DO3A-S01-GCG radioactivity administration, to calculate the plasma-to-whole blood concen-
tration ratios.
For NHP 5–7, venous blood samples were taken at 5, 30 and 60 min for assessment of in vivo metabolic 
stability of [68Ga]Ga-DO3A-S01-GCG, using HPLC methods described below. The percentage of intact [68Ga]
Ga-DO3A-S01-GCG was plotted against time from administration and fitted to a mono-exponential function.
PET procedures: Test-retest reproducibility and receptor occupancy after pre-treatment with 
acylated specific GCGR agonist 1-GCG. Test-retest and receptor occupancy studies were performed in 
NHPs (n = 5, weight 5.0 ± 1.2, range 3.8–6.5 kg) by PET/CT at the UU site, using the parameters optimised in the 
dose escalation study described above.
In the morning, a baseline [68Ga]Ga-DO3A-S01-GCG PET/CT dynamic examination over 90 minutes was 
performed (i.e. [68Ga]Ga-DO3A-S01-GCG compound corresponding to approximately 0.05 µg/kg peptide mass, 
as determined having negligible peptide mass in the dose escalation study).
After the baseline PET examination, the NHP was administered a study drug (i.e. phosphate buffered saline 
(PBS) in case of the test-retest study or 30 µg/kg 1-GCG, an acylated selective GCGR agonist, in PBS subcutane-
ously (Table 2). The structure 1-GCG and the model of binding to the GCGR is shown in Fig. 1B,D. The pharma-
cological effects of 1-GCG were described previously7. Two hours post study drug (at ~cmax of the test compound), 
a second 90 minutes dynamic PET examination was performed with [68Ga]Ga-DO3A-S01-GCG (again adminis-
tered at radioactive levels corresponding to negligible mass effect to avoid significant receptor occupancy induced 
by the radiotracer itself), to investigate the changes in liver binding due to the 1-GCG intervention.
ID NHP 1 NHP 2 NHP 3 NHP 4 NHP 5 NHP 6 NHP 7
Weight (kg) 5.4 6.0 5.4 6.7 4.4 3.4 4.1
Scan 1
µg/kg 0.2 0.09 0.08 0.05 0.045 0.051 0.044
MBq/kg 1.0 1.3 0.6 0.4 0.7 0.8 0.7
Scan 2
µg/kg 13 1.0 2.7 0.47 — — —
MBq/kg 3.2 2.6 3.3 0.7 — — —
Scan 3
µg/kg 27 6 67 61 — — —
MBq/kg 7.9 9.9 10.1 8 — — —
Table 1. Dosing of [68Ga]Ga-DO3A-S01-GCG and corresponding co-injection of DO3A-S01-GCG peptide 
mass for each NHP experimental day.
ID NHP 8 NHP 9 NHP 10 NHP 11 NHP 12
Weight 3.9 6.1 4.0 6.4 4.5
Type T/R T/R T/R R.O. R.O.
Scan 1
µg/kg 0.041 0.029 0.086 0.034 0.043
MBq/kg 0.7 0.5 0.3 0.7 0.7








µg/kg 0.033 0.034 0.069 0.042 0.051
MBq/kg 0.5 0.5 0.2 0.6 0.9
Table 2. Administration of [68Ga]Ga-DO3A-S01-GCG and study drug for the test-retest and receptor 
occupancy studies. T/R: Test-retest and R.O.: Receptor occupancy.
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Metabolic stability of [68Ga]Ga-DO3A-S01-GCG. Blood samples were centrifuged at 4000 rpm for 
2 minutes at 4 °C (Beckman Allegra X-22R Centrifuge, Palo Alto, USA). From the plasma, 0.5 ml was taken and 
an equal volume of acetonitrile was added to precipitate the proteins. The mixture was centrifuged at 13200 rpm 
at 4 °C for 1 min (Eppendorf 5415 R centrifuge, Eppendorf AG, Hamburg, Germany). The supernatant was filtered 
through a 0.2 μm nylon membrane (Corning Incorporated, Corning, NY, USA) by centrifugation at 13200 rpm 
at 4 °C for 1 min. 500 µl of the filtered supernatant was diluted with 1500 µl H2O; thereafter, 30 µl of 0.01 mM 
unlabelled DO3A-S01-GCG was added to the mixture. The sample preparation recovery was determined by 
measuring the radioactivity in the plasma, filters and pellet.
HPLC analysis was performed using a binary pump system (Gilson, Middleton, USA). The sample (1.8 ml) 
was injected using an automated solid phase extraction controller (ASPEC Gilson) connected to a dilutor 
(Gilson). The separation was performed on an Xbridge Prep BEH130 C18 (peptide separation technology) 
250 mm × 10 mm, 5 µm with a 10 × 10 mm C18 security guard from the same supplier. The HPLC system was 
operated at a flow rate of 6 ml/min. The mobile phase consisted of 0.1% TFA in MilliQ: 0.1% TFA in Acetonitrile. 
Gradient elution mode was used for the separation (Gradient: 0–7 min: 5–70%, 7–12 min: 70%, 12–13 min: 
70–5%, 13–15 min: 5%).
A second method was developed with a lesser gradient, to determine if any metabolites were co-eluting with 
the DO3A-S01-GCG peak. A UV detector (Gilson) was used to detect unlabelled DO3A-S01-GCG at 220 nm. 
The outlet from the detector was connected to a switching valve on the arm of the ASPEC to enable automatic 
fraction collection. Six fractions were collected, and the radioactivity in the fractions was measured by a well-type 
scintillation counter. A radio detector (Radiomatic 610TR, Packard, USA) was coupled in series with the UV 
detector.
Image data processing. Image processing at each site was performed according to standard optimised 
procedures for each respective PET scanner. At the UUH facility, the PET list mode data were reconstructed into 
33 frames (12 × 10 s, 6 × 30 s, 5 × 120 s, 5 × 300 s, 5 × 600 s) using an iterative Q-Clear 200 algorithm. At the KI 
facility, the PET list-mode data were reconstructed into 38 frames (9 × 10 s, 2 × 15 s, 3 × 20 s, 4 × 30 s, 4 × 60 s, 
4 × 180 s, 12 × 360 s) using the ordinary Poisson-3D-ordered subset expectation maximisation (OP-3D-OSEM) 
algorithm (10/16 iterations/subsets, including modelling of the point spread function). For SUV analysis, the 
frames were later resampled to the framing sequence used at the Uppsala site.
PET data analysis. PET image analysis was performed by the PMOD 3.7 software (PMOD Technologies 
Ltd. Zurich, Switzerland). Regions of Interest (ROIs) were segmented on transaxial PET projections assisted by 
co-registered CT images if available. Tissues (liver, spleen, heart, aorta, kidney, skeletal muscle, lung, pancreas, 
bone and intestine) were segmented on transaxial projections and combined into Volumes of Interest (VOIs). For 
the liver, the portal vein and the vena cava were excluded by assistance of CT, as well as comparison of early and 
late image summations.
To determine an image-derived arterial input function, single pixel ROIs were placed in the aorta to avoid 
partial volume effects. For the PET examinations performed at KI, ROIs for the liver, spleen, heart, aorta and 
kidney were delineated based on the summation images of the third PET measurement from each experimental 
day, for which highest radioactivity was injected due to the dose escalation study design. There was no or minimal 
movement of the NHP during the day, as the body was fixated in a bear hugger at both sites. The dynamic PET 
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Graphical analysis as described by Logan et al.8 was applied to the PET dynamic data from the liver (target 
tissue) and spleen (expected to have minimal GGCR expression) (PKIN module, PMOD 3.7 software, PMOD 
Technologies Ltd. Zurich, Switzerland). Volume of Distribution (Vt) was calculated using image-derived aortic 
curves as input. The aortic input curve was corrected for the plasma-to-whole blood ratios obtained from blood 
sampling taken during each experiment. The aortic input curve was also corrected for the metabolic stability, i.e. 
the percentage of native [68Ga]Ga-DO3A-S01-GCG remaining in the blood. Goodness of fit for the model fitting 
was performed in the PKIN module using the standard assessments including Chi2, Sum-of-squares and R2.
For the dose escalation study, Vt of the liver and spleen was plotted against the administered peptide mass 
dose (µg/kg) to determine the peptide mass doses, which induce negligible mass effect (baseline), the background 
binding and the in vivo dissociation constant (Kd, defined as the peptide mass dose, which induces 50% occu-
pancy of the receptor population in the dynamic range).
In vitro autoradiography of spleen. Splenic binding of [68Ga]Ga-DO3A-S01-GCG was previously 
observed in rat in vivo5. This assay was performed to elucidate if splenic binding in human and NHP in vivo 
would be expected.
Spleen tissue was collected post-mortem from the NHP and Sprague Dawley rat. Biopsies from donor human 
spleen were obtained from Uppsala Biobank (sample collection 827) and approved by local ethical review board 
(Drn 2016/465).
The splenic biopsies were processed to 10 µm frozen tissue sections by a cryotome. The sections were 
pre-incubated in phosphate-buffered saline (PBS) (pH 7.4, 1% Bovine Serum Albumin (BSA)) for 10 min at room 
temperature (RT). Then, the sections were incubated with 5 nM [68Ga]Ga-DO3A-S01-GCG in 150 mL PBS (pH 
7.4, 1% BSA), either alone or in the presence of 10 µM GCG or 1 µm DO3A-S01-GCG precursor for 60 min at RT.
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After incubation, the sections were washed three times, first with assay buffer (PBS pH 7.4 1% BSA) and 
then twice with PBS for 1 minute. Sections were carefully dried at 37 °C and then exposed against a digital phos-
phorimager plate, together with a 20 µl reference from the buffer calibrated against a gamma-counter to ena-
ble quantification to fmol bound radioligand/mm3. The phosphorimager plates were scanned using a Cyclone 
Plus Phosphor imager (Perkin Elmer) at 600 dpi, and the resulting autoradiograms analysed by ImageJ (NIH, 
Bethesda). The assay was repeated three times.
Human predicted dosimetry. The predicted dosimetry of [68Ga]Ga-DO3A-S01-GCG in human males 
was estimated based on the in vivo biodistribution in NHPs as captured by dynamic PET examinations. The base-
line PET examinations in NHP 2–7 (n=6) were averaged for the dosimetry analysis. Since the FOV of the PET 
scanner excluded dynamic recordings from the head and hind-limbs, we do not have complete biodistribution 
data for estimating dosimetry. However, the uptake in the brain in NHP is likely negligible based on observa-
tions in rat (5) as well as a whole-body PET/CT examination performed on NHP1 90–120 minutes post [68Ga]
Ga-DO3A-S01-GCG administration.
The dosimetry calculations were performed as described previously for [68Ga]Ga-DO3A-VS-Cys40-Exendin44 
and [68Ga]Ga-DO3A-S01-GCG in rat5.
In brief, dynamic NHP organ uptake as measured by PET and expressed as SUV was normalised to that of 
human organs (using tissue weights of whole-body adult reference phantoms). The decay-corrected and normal-
ized SUVs were back-corrected to count rates to calculate the actual radiation burden in each tissue. The tissue 
residence times (MBq-h/MBq) were assessed by trapezoidal approximation of the un-decay corrected human 
SUV biodistribution data. The tissue washout from the last time point (90 minutes) until infinity was estimated 
by a single mono-exponential fit.
The estimation of the absorbed dose was performed by the OLINDA/EXM 1.1 software, where the calcula-
tions were based on the adult reference male or female phantoms to obtain the absorbed dose estimate in humans 
(ICRP60). The organ specific doses are reported as mGy/MBq (effective dose as mSv/MBq). The amount of MBq 
that can be safely administered annually (MBq/year) was calculated for each organ as well as the effective dose, by 
dividing the limiting dose (10 mSv/year for the effective dose, 150 mGy/year for all tissues except for red marrow 
with 50 mGy/year) by the dose (mGy/MBq or mSv/MBq).
Statistical considerations. Data on group level are reported as means ± SEM. Statistical analysis was per-
formed in GraphPad Prism 6.05, and differences between groups were assessed by the students t-test using a 
significance level of p < 0.05.
Ethical approval. All applicable international, national and/or institutional guidelines for the care and use 
of animals were followed.
Results
Radiochemistry. The radiochemical purity was 97.2 ± 1.6% (n = 28) with no unknown impurity of over 5%. 
Molar activity values varied depending on the age of the generator and were, on average, 95.96 ± 25.22 MBq/nmol 
(range 50–140 MBq/nmol) at the end of the synthesis. The reproducibility was high with non-decay corrected 
radiochemical yield of 59.3 ± 1.9 and success rate of 100%.
Biodistribution in non-human primate. The biodistribution is based on the baseline scans of NHP 2–7 
(n = 6). Early accumulation was seen in the vasculature and the cardiac ventricles (Fig. 2A, far left panel). A few 
minutes following administration, accumulation visibly occurred in liver, which has a high expression of GCGR 
(Fig. 2A, mid left panel). Clearance from the vasculature was apparent after 20 minutes while the liver binding 
was retained (Fig. 2A, mid right panel). At the late stages of the PET examinations, radioactivity retention was 
observed only in the liver and kidney (Fig. 2A, far right panel). The kidney accumulation was concentrated to 
kidney cortex. Quantification of [68Ga]Ga-DO3A-S01-GCG biodistribution by SUV calculation confirmed that 
radioactivity retention occurred in the liver and kidney, while the tracer was cleared in all other examined tissues 
(Fig. 2B).
SUV analysis of dose escalation study. Table 1 describes the dose escalation study design with the 
administered [68Ga]Ga-DO3A-S01-GCG radioactivity and administered DO3A-S01-GCG peptide mass for each 
PET examination in each NHP.
Coronal Maximum Intensity Projections (MIPs, summed 0–90 minutes) of all PET examinations in the study 
visualised the strong accumulation of [68Ga]Ga-DO3A-S01-GCG in the liver and kidney (Fig. 3A). Increasing 
the co-injected DO3A-S01-GCG peptide mass progressively reduced the visual accumulation in the liver but 
not kidney. Temporally resolved SUV time-activity curves confirm the dose dependent decrease in [68Ga]
Ga-DO3A-S01-GCG retention in liver (Fig. 3B). No competition effect was seen in the spleen (Fig. 3C).
SUV90min was chosen as endpoint since retention differences were increasingly pronounced at later 
time-points. Dose-dependency was seen for the reduction in SUV90min in the liver (Fig. 3D). NHPs receiving 
[68Ga]Ga-DO3A-S01-GCG solutions spiked with >5 µg/kg of co-injected peptide exhibited decreased binding 
(SUV90min = 1.35 ± 0.29, variability 21.4%) compared to NHPs that received [68Ga]Ga-DO3A-S01-GCG tracer 
only (defined as <0.2 µg/kg co-injected peptide) (SUV90min = 3.93 ± 0.67, variability 17.0%) (p < 0.0001) (Fig. 3E).
Logan graphical analysis of dose escalation study. Metabolite stability analysis in venous plasma 
(n = 3) showed that the majority of radioactivity corresponded to intact [68Ga]Ga-DO3A-S01-GCG (95.9 ± 1.2% 
after 5 minutes, 89.0 ± 2.7% after 30 minutes and 80.3 ± 3.3% after 60 minutes). Based on the low observed 
inter-individual variability in [68Ga]Ga-DO3A-S01-GCG metabolic stability, a population-based model was 
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applied to the graphical analysis in all NHPs. The plasma-to-whole blood ratios, used for correction of the image 
derived aortic input curve, were linear with time for all examinations and varied between 1.4 and 1.6.
Vt as estimated by Logan graphical analysis using metabolite corrected image derived arterial plasma input 
showed strong dose dependency (Fig. 4A). Negligible mass effect (defined as <5% occupancy incurred from 
baseline 3.2 µg/kg, green dotted line) was achieved at DO3A-S01-GCG doses below approximately 0.2 µg/kg. 
The in vivo Kd in the liver, i.e. 50% incurred occupancy from baseline in the dynamic range (grey shaded area) 
above the background (red dotted line), was estimated to 0.7 µg/kg. Peptide mass dose escalation of co-injected 
DO3A-S01-GCG progressively decreased the Vt parameter to levels where only minor further additional blocking 
effect was seen (background level Vt = 0.9). Vt in the spleen was low for all PET examinations and unaffected by 
competition, as required from a suitable reference tissue. Group analysis of co-injected peptide doses >5 µg/kg 
(Vt = 1.11 ± 0.13, variability 11.5%) decreased the binding compared to administration of doses with negligible 
mass effect <0.2 µg/kg (Vt = 3.16 ± 0.31, variability 9.9%) (p < 0.0001) (Fig. 4B). The occupancy incurred in the 
liver by co-injection of the different doses of DO3A-S01-GCG peptide, calculated from the decrease in [68Ga]
Ga-DO3A-S01-GCG binding from baseline Vt = 3.2, reached maximally 72% (Fig. 4C). Liver SUV90min as simpli-
fied endpoint correlated linearly with the Logan derived Vt (Fig. 4D).
Test-retest reproducibility and receptor occupancy after pre-treatment with an acylated spe-
cific GCGR agonist. Test-retest reproducibility of [68Ga]Ga-DO3A-S01-GCG binding in the liver, as assessed 
over the course of the same day by pre-treatment with PBS before follow-up scanning, was 5.7 ± 7.9% (n = 3) 
(Fig. 4E). Pre-treatment with an acylated specific GCGR agonist, 1-GCG, at a dose of 30 µg/kg, on the other hand, 
resulted in a distinct decrease in the liver binding of 61.5 ± 9.1% (n = 2) (Fig. 4F).
In vitro autoradiography of [68Ga]Ga-DO3A-S01-GCG in the spleen. Previously, we reported selec-
tive in vivo binding of [68Ga]Ga-DO3A-S01-GCG in rat spleen in biodistribution studies5. In the NHP biodis-
tribution study described above, no splenic uptake, or effect by competition, was seen. In vitro autoradiography 
studies of splenic sections were therefore performed to understand if binding is to be expected in the human 
spleen.
[68Ga]Ga-DO3A-S01-GCG binding to sections of rat spleen was strong, and could be blocked to a similar 
degree by co-incubation with both endogenous glucagon and unlabelled DO3A-S01-GCG precursor peptide in 
excess (Fig. 5).
The binding of [68Ga]Ga-DO3A-S01-GCG to splenic sections from NHP and human was lower than in rat. 
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Figure 2. Biodistribution of [68Ga]Ga-DO3A-S01-GCG in NHP. Representative Maximum Intensity 
Projections (MIP) of biodistribution at four different time-points following [68Ga]Ga-DO3A-S01-GCG 
administration. (A) Quantification of tissue biodistribution by SUV measurements show that radioactivity 
retention occurs in the liver as well as kidney, while remaining tissues exhibit clearance of the radioactivity 
signal. (B) Bars represent averages ± SD from PET/CT examinations in n = 6 NHPs.
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Human predicted dosimetry. The predicted human dosing per MBq administered [68Ga]
Ga-DO3A-S01-GCG as extrapolated from NHP biodistribution is presented in Fig. 6A. Kidneys received the 
highest absorbed dose (0.29 mGy/MBq, red bar), followed by the heart wall (myocardium) (0.10 mGy/MBq) and 
liver (0.049 mG/MBq). Red marrow received 0.039 mGy/MBq. The effective dose of [68Ga]Ga-DO3A-S01-GCG 
was 20.6µSv/MBq.
Based on the absorbed dose and the annual limit for absorbed dose for each tissue, there is a limit of 485 MBq 
[68Ga]Ga-DO3A-S01-GCG annually, where the effective dose is limiting (Fig. 6B). The critical organ is the kidney, 
which would allow for an annual administration of 519 MBq [68Ga]Ga-DO3A-S01-GCG. The absorbed dose for 
[68Ga]Ga-DO3A S01-GCG in red marrow of NHP predicts an annual exposure limit for humans in excess of 
1000 MBq.
Discussion
We present evidence of a first-in-class radioligand, capable of sensing and quantifying drug activity at the GCGR 
in vivo in NHP by PET. [68Ga]Ga-DO3A-S01-GCG was previously evaluated in vitro and in vivo in rat, wherein 
nanomolar affinity and strong specificity for the GCGR were demonstrated5. [68Ga]Ga-DO3A-S01-GCG bound 
in rat liver in vivo in a receptor mediated manner. Here, we demonstrate that the results also translate into a large 
animal model with high fidelity for human physiology.
When using a radioligand to study a receptor system in a relatively unperturbed physiological baseline state 
(ignoring possible effects of anesthesia), it is imperative that the administered radioligand mass itself does not 
illicit a mass effect i.e. does not carry a molar abundance that significantly affects the receptor system. Negligible 
mass effect of a radioligand is usually defined as exerting less than 5% receptor occupancy.
The dose escalation study was primarily intended to reveal the upper limit of mass injection not evoking signif-
icant receptor occupancy. In addition, the procedure allowed us to evaluate the proportionality between admin-
istered competing DO3A-S01-GCG peptide dose and the magnitude of binding of [68Ga]Ga-DO3A-S01-GCG in 
liver. The increase in radioactivity for each subsequent PET examination means that residual remaining radioac-
tivity in the NHP from previous examinations during the same experimental day will be negligible. The increase 
in peptide mass (dose escalation) for each subsequent PET/CT examination means that the previously adminis-
tered peptide mass during the experimental day will be negligible or very low in comparison.
NHPs were dosed with [68Ga]Ga-DO3A-S01-GCG corresponding from 0.04 µg/kg up to 67 µg/kg 
DO3A-S01-GCG peptide mass. Due to the limit imposed by molar activity, it was not possible to adminis-
ter a mass dose less than 0.04 µg/kg while still retaining sufficient injected radioactive signal. The binding 
in the liver, using either Vt or the simpler SUV90min, showed clear dose dependency. The in vivo Kd of [68Ga]
Ga-DO3A-S01-GCG in the dynamic range in the liver was 0.7 µg/kg, which is in line with the strong potency for 
NHP GCGR demonstrated in vitro5. The maximal binding plateaued at approximately Vt = 3.2. DO3A-S01-GCG 
peptide mass doses <0.2 µg/kg were estimated to induce negligible mass effect. Assuming that the NHP data are 
predictive of the human situation, this implies that [68Ga]Ga-DO3A-S01-GCG should be administered in doses 
<0.2 µg/kg in clinical trials for accurate measurement of GCGR occupancy in the liver.
Only minor additional competition effect was seen for administered doses in excess of 6 µg/kg. [68Ga]
Ga-DO3A-S01-GCG background binding in the liver was approximately Vt = 0.9, which indicated a retention 










































































































Figure 3. In vivo competition of [68Ga]Ga-DO3A-S01-GCG in NHP. Maximum Intensity Projections (MIPs, 
summed 0–90 minutes) of all PET examinations in the study, ranked after ascending DO3A-S01-GCG peptide 
mass dose. (A) SUV quantification of the dynamic uptake for all PET examinations in the liver (B) and spleen 
(C). SUV90min as endpoint for liver binding of [68Ga]Ga-DO3A-S01-GCG was inversely proportional to the 
increase in co-injected DO3A-S01-GCG peptide mass dose. (D) There was a clear difference in liver binding, 
assessed as SUV90min, between the groups with the lowest (<0.2 µg/kg) and highest (≥5 µg/kg) administered 
peptide mass doses. ****Indicate p < 0.001.
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process that differs from, for example, the spleen where the background binding was approximately Vt = 0.4. This 
residual background signal in the liver was the reason for not achieving more than 72% occupancy at the highest 
competing doses. Xenobiotics are often metabolised in the liver, which may partly account for the slightly ele-
vated hepatic background. Pre-treatment with a high dose (30 µg/kg) of acylated selective GCGR agonist, 1-GCG, 
resulted in a similar magnitude of occupancy, up to almost 70%. In a previous study, 1-GCG was tested at 30 µg/
kg with repeated s.c. dosing in obese diabetic NHP over 4 weeks, where it led to elevated glucose excursion and 
increased diabetogenic risk whereas, when dosed on top of a selective GLP-1R agonist, it led to increased body 
weight loss but somewhat impaired glucose control compared to treatment with the selective GLP-1R alone7.























































































































Figure 4. Logan graphical analysis of [68Ga]Ga-DO3A-S01-GCG binding. Logan derived Vt in the liver and 
spleen plotted against co-injected DO3A-S01-GCG peptide mass dose (A), where the green dotted line indicates 
<5% occupancy i.e. negligible mass effect, the blue dotted line indicates in vivo Kd, the red dotted line indicates 
the background. Co-injected peptide doses >5 µg/kg strongly and consistently decreased the liver binding of 
[68Ga]Ga-DO3A-S01-GCG compared to administration of doses with negligible mass effect. (B) Occupancy 
incurred by co-injected amount of DO3A-S01-GCG peptide mass dose. (C) Correlation between Logan derived 
Vt and SUV90min in the liver (D). ****Indicates p < 0.0001. Test-retest variability of [68Ga]Ga-DO3A-S01-GCG 
binding in the liver over the course of an experimental day. (E) Effect on [68Ga]Ga-DO3A-S01-GCG binding in 
the liver by pre-treatment with 30 µg/kg of the acylated GCGR agonist 1-GCG (F).



































Figure 5. In vitro autoradiography of [68Ga]Ga-DO3A-S01-GCG binding in frozen sections of spleen. 
[68Ga]Ga-DO3A-S01-GCG binding in rat could be inhibited by both endogenous glucagon and unlabelled 
DO3A-S01-GCG in excess. No strong binding was seen in splenic sections from NHP or human, and co-
incubation with endogenous glucagon or unlabelled DO3A-S01-GCG did not affect the binding. Bars represent 
















































































































































































































































































Figure 6. Human dosimetry of [68Ga]Ga-DO3A-S01-GCG as predicted from NHP biodistribution. The human 
predicted tissue specific absorbed dose and effective dose (in mSV/MBq) of [68Ga]Ga-DO3A-S01-GCG. (A) 
The maximal possible annual radioactive dosing of [68Ga]Ga-DO3A-S01-GCG, based on the human predicted 
absorbed dose and the annual radiation safety limits. (B) Red bars indicate the critical organ. Logarithmic scale 
(Y-axis) is used for both panels.
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The Logan graphical model provided acceptable goodness of fit for the PET data from all scans regardless 
magnitude of liver binding, including the baseline scans (Chi2 = 4.9, R2 = 0.987), the full precursor blockade scans 
(Chi2 = 2.1, R2 = 0.999), the 1-GCG pre-treatment scans (Chi2 = 4.8, R2 = 0.996) and the re-test scans (Chi2 = 2.0, 
R2 = 0.996).
There was a linear correlation between Vt and SUV90min, indicating that SUV90min can serve as a simplified 
estimate for GCGR occupancy. However, SUV90min exhibited larger variability on a group level (SUV90min vari-
ability = 17.0%) than Vt (Vt variability = 9.9%), which uses a larger portion of the dynamic examination for its 
calculation. By using the image-derived arterial plasma, corrected for metabolic stability, as input for advanced 
image analysis, it was possible to correct for individual differences in blood flow, radioligand metabolic stability, 
clearance from the vasculature, etc. These corrections to the tissue radioactive signal are designed to increase pre-
cision of the measurement, which is particularly important when considering quantification of occupancy on a 
receptor. Vt is therefore recommended for highest possible precision in measurement, despite the more demand-
ing analysis process. The current study was performed on two different PET scanners with different spatial reso-
lution. However, partial volume effects are not expected given the large size of the liver compared with individual 
pixels. For the delineation of aorta, only single pixels deemed within lumen were included for the image derived 
input signal, to minimize any partial volume effects regardless of scanner.
No specific [68Ga]Ga-DO3A-S01-GCG binding was observed in the NHP spleen as opposed to in rat spleen5. 
Spleen was therefore proposed as a reference tissue due to its proximity to the liver (i.e. fitting in the same PET 
FOV), the relative ease of delineation and importantly the lack of specific binding of [68Ga]Ga-DO3A-S01-GCG 
in either NHP or human splenic sections as demonstrated by autoradiography. Specific bone marrow uptake was 
also seen in rat, but not in NHP. GCGR expression on the protein level has not been reported in either human 
spleen or bone marrow in the Human Protein Atlas9. Thus, neither spleen nor bone marrow binding of [68Ga]
Ga-DO3A-S01-GCG is expected in human.
The kidney uptake was not affected by the dose escalation, strongly indicating that it is not mediated by GCGR 
uptake. Radiolabelled small peptides are often excreted in urine and reabsorbed by the renal tubules in the kid-
ney cortex10. Generally, residualising radiometal-based peptide PET tracers (such as Gallium-68 based ones) are 
trapped in the renal tubules following the reabsorption, and it is highly likely that the kidney uptake of [68Ga]
Ga-DO3A-S01-GCG as seen here is mediated by this process.
Binding of [68Ga]Ga-DO3A-S01-GCG in GLP-1R rich pancreas was low (SUV90min < 1), thus, fur-
ther reinforcing the lack of cross-binding. As comparison, the GLP-1R selective PET radioligand [68Ga]
Ga-DO3A-VS-Cys40-Exendin-4 exhibits strong pancreatic binding (SUV90min > 6), while displaying negligible 
binding in the liver4.
The manual preparation of [68Ga]Ga-DO3A-S01-GCG yielded a molar activity (i.e. the efficiency of the 
radiolabelling, or the amount of MBq radioactivity incorporated per nanomole of the peptide) of, on average, 
almost 100 MBq/nmol at the end of the synthesis. The preparation method demonstrated high reproducibility 
with 100% success rate, and the variation in molar activity values was solely due to the age of the generator and 
thus total radioactivity amount available. Even the minimal value of 50 MBq/nmol allowed for low adminis-
tered peptide mass while providing sufficient radioactivity for statistically relevant counts and high-quality PET 
images. However, a clinical study would require good manufacturing practice compliant automation of [68Ga]
Ga-DO3A-S01-GCG production, which may result in lower achievable SRA. Assuming a human weight of 75 kg, 
administered radioactivity dose of 1 MBq/kg, and SRA of 30 MBq/nmol, preliminary estimation showed that the 
administered peptide dose would correspond to 0.17 µg/kg. Such low peptide dose would assure adequate assess-
ment of GCGR receptor occupancy in humans.
The human predicted dosimetry of [68Ga]Ga-DO3A-S01-GCG extrapolated from NHP exhibited some dis-
crepancies from the dosimetry calculation based on rat biodistribution published previously5. The most pro-
nounced discrepancy was the higher absorbed dose to the kidneys in rat compared to NHP. In contrast, most 
other organs showed lower absorbed doses based on rat data. This is possibly due to a more rapid metabolism in 
wake rats compared to anaesthetised NHPs, where faster clearance from the blood stream leads to faster reab-
sorption and trapping in renal tubules – i.e. increased renal exposure. The radioactivity in the blood as well as in 
most peripheral tissues is consequently higher in NHP than in rat due to comparatively lower excretion in the 
larger animal model. The dosimetry calculation takes cross-firing (i.e. the radioactive dosing to an organ from a 
neighbouring tissue) from the blood stream into account for tissue-absorbed dose. This is especially noticeable in 
the heart wall based on NHP data, which receives the majority of its dose from passing blood volume.
Human predicted dosimetry as extrapolated from NHP allows for annual administration of IV 485 MBq 
[68Ga]Ga-DO3A-S01-GCG based on the effective dose and >500 MBq based on the critical organ kidney, mean-
ing that GCGR occupancy can be measured repeatedly in humans without exceeding radiation safety limits. 
Assuming a radioactivity dose of 1 MBq/kg [68Ga]Ga-DO3A-S01-GCG for human studies (75 MBq in a 75 kg 
individual), up to 6 PET examinations of GCGR occupancy could potentially be performed annually. [68Ga]
Ga-DO3A-S01-GCG is therefore suitable for interventional studies, where repeated examinations are required.
In the context of dual GLP-1/GCG receptor agonist development, [68Ga]Ga-DO3A-S01-GCG as a PET radi-
oligand provides the means to demonstrate target engagement at the GCGR early in the drug development pro-
cess. GLP-1R radioligand [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 has similarly been employed for showing target 
engagement of intravenously administered Exendin-4 in the pancreas11.
These two complementing tools potentially give access to direct quantification of drug activity at both the 
GCGR and GLP-1R in humans, and are expected to assist in unravelling the contribution of respective hormone 
receptors to the beneficial physiological effects seen during dual GLP-1/GCG receptor agonist treatment.
In summary, first-in-class GCGR PET radioligand [68Ga]Ga-DO3A-S01-GCG bound specifically in the NHP 
liver and could be competed away dose-dependently. Occupancy at the GCGR was quantifiable and dose depend-
ent. Administration of [68Ga]Ga-DO3A-S01-GCG at peptide doses <0.2 µg/kg incurred negligible mass effect 
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and constituted GCGR imaging at basal undisturbed physiological conditions. Test-retest reproducibility was 
excellent, and proof-of-concept for in vivo assessment of occupancy at the GCGR in the liver was demonstrated 
with an acylated glucagon agonist. Repeated examinations can be performed in humans without exceeding radia-
tion safety limits. [68Ga]Ga-DO3A-S01-GCG has the potential to become an important tool in dual GLP-1/GCG 
receptor agonist drug candidate selection and optimisation in clinical trials.
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